Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 249.37 Bil Enterprise Value: 272.91 Bil PE Ratio: 20.67 PB Ratio: 5.61 GF Score: 81/100

Merck & Co Inc at SVB Leerink Global Healthcare (Virtual) Transcript

Feb 17, 2022 / 09:20PM GMT
Release Date Price: $76.75 (-0.97%)
Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD of Immuno-Oncology & Senior Research Analyst

Hello, everyone. Welcome to our session this afternoon with Merck. I am really pleased to host Caroline Litchfield and Peter Dannenbaum.

And if you don't know me, I am the immuno-oncology analyst here at SVB Leerink. You may say, "Well, why do you cover Merck?" And it is because immuno-oncology is important to Merck. And actually, I love it because I love thinking about things other than immuno-oncology as well. And so always happy to talk with Merck management and really excited to have you both with us today.

Caroline Litchfield
Merck & Co., Inc. - Executive VP & CFO

Thank you, Daina.

Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD of Immuno-Oncology & Senior Research Analyst

And one point of process for people listening, if you'd like me to pose a question to Caroline or Peter, please look at the box below my finger, put it there. If you e-mail it to me, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot